Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities: 2011-2024

Historic Gains from Investment Securities for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Dec 2024 value amounting to $13.1 million.

  • Catalyst Pharmaceuticals' Gains from Investment Securities was N/A to $219,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $75.2 million, marking a year-over-year change of. This contributed to the annual value of $13.1 million for FY2024, which is 7.76% down from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $13.1 million for FY2024, which was down 7.76% from $14.2 million recorded in FY2023.
  • Catalyst Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $31.9 million during FY2022, with a 5-year trough of $56,000 in FY2020.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Gains from Investment Securities value was $14.2 million (recorded in 2023), while the average stood at $19.7 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Gains from Investment Securities soared by 20,737.25% in 2022 and then tumbled by 55.53% in 2023.
  • Catalyst Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $56,000 in 2020, then skyrocketed by 173.21% to $153,000 in 2021, then soared by 20,737.25% to $31.9 million in 2022, then tumbled by 55.53% to $14.2 million in 2023, then declined by 7.76% to $13.1 million in 2024.